TScan Therapeutics, Inc.

830 Winter Street

Waltham, Massachusetts 02451

May 15, 2023

Via EDGAR Transmission

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268260)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), TScan Therapeutics, Inc. (the “Company”) hereby (a) withdraws its previous acceleration request, dated May 10, 2023, for the above referenced registration statement, as amended (the “Registration Statement”), and (b) requests that the effective date of the Registration Statement be accelerated to May 16, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447.


TScan Therapeutics, Inc.

/s/ Brian Silver

Name: Brian Silver
Title: Chief Financial Officer



William D. Collins, Esq., Goodwin Procter LLP